Development and therapeutic implications of selective histone deacetylase 6 inhibitors

JH Kalin, JA Bergman - Journal of medicinal chemistry, 2013 - ACS Publications
JH Kalin, JA Bergman
Journal of medicinal chemistry, 2013ACS Publications
This Perspective provides an in depth look at the numerous disease states in which histone
deacetylase 6 (HDAC6) has been implicated. The physiological pathways, protein–protein
interactions, and non-histone substrates relating to different pathological conditions are
discussed with regard to HDAC6. Furthermore, the compounds and methods used to
modulate HDAC6 activity are profiled. The latter half of this Perspective analyzes reported
HDAC6 selective inhibitors in terms of structure, potency, and selectivity over the other …
This Perspective provides an in depth look at the numerous disease states in which histone deacetylase 6 (HDAC6) has been implicated. The physiological pathways, protein–protein interactions, and non-histone substrates relating to different pathological conditions are discussed with regard to HDAC6. Furthermore, the compounds and methods used to modulate HDAC6 activity are profiled. The latter half of this Perspective analyzes reported HDAC6 selective inhibitors in terms of structure, potency, and selectivity over the other HDAC isoforms with the intent of providing a comprehensive overview of the molecular tools available. Potential obstacles and future directions of HDAC6 research are also presented.
ACS Publications